
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp's positive outlook is supported by its projected revenue growth, with an estimated increase of 26% quarter-over-quarter for 4Q25, translating to approximately $84.8 million. The company's MACI product line is anticipated to experience volume growth in the low-to-mid teens, along with an estimated 21.2% year-over-year growth for FY26, driven by an average conversion rate of about 31.6% of biopsies to MACI. Additionally, the annual increase in average selling prices (ASPs) for MACI, projected to rise between 300 to 500 basis points, further underpins the company's sustainable revenue growth trajectory.
Bears say
Vericel Corp faces a negative outlook primarily due to lowered revenue expectations for its MACI product in fiscal years 2026 and 2027, with a reduction of approximately 200 basis points. Additionally, there are significant risks related to slower adoption rates for MACI and MACI Arthro, as well as challenges in burn care sales and potential disruptions stemming from sales force expansion. If the company fails to meet top-line expectations in any given quarter, it may result in shares dropping to historically low valuation points.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares